CN115137737A - RNA delivery system for treating pulmonary fibrosis - Google Patents
RNA delivery system for treating pulmonary fibrosis Download PDFInfo
- Publication number
- CN115137737A CN115137737A CN202210325708.9A CN202210325708A CN115137737A CN 115137737 A CN115137737 A CN 115137737A CN 202210325708 A CN202210325708 A CN 202210325708A CN 115137737 A CN115137737 A CN 115137737A
- Authority
- CN
- China
- Prior art keywords
- rna
- sequence
- pulmonary fibrosis
- delivery system
- targeting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000005069 pulmonary fibrosis Diseases 0.000 title claims abstract description 75
- 239000013603 viral vector Substances 0.000 claims abstract description 67
- 239000003814 drug Substances 0.000 claims abstract description 32
- 238000011282 treatment Methods 0.000 claims abstract description 31
- 210000004072 lung Anatomy 0.000 claims abstract description 15
- 210000000056 organ Anatomy 0.000 claims abstract description 15
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 154
- 230000008685 targeting Effects 0.000 claims description 83
- 239000002924 silencing RNA Substances 0.000 claims description 68
- 108020004459 Small interfering RNA Proteins 0.000 claims description 58
- 239000012634 fragment Substances 0.000 claims description 53
- 210000001808 exosome Anatomy 0.000 claims description 38
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 35
- 210000001519 tissue Anatomy 0.000 claims description 35
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 34
- 241000700605 Viruses Species 0.000 claims description 31
- 108090000623 proteins and genes Proteins 0.000 claims description 22
- 230000000295 complement effect Effects 0.000 claims description 21
- 239000013598 vector Substances 0.000 claims description 20
- 239000002773 nucleotide Substances 0.000 claims description 16
- 125000003729 nucleotide group Chemical group 0.000 claims description 16
- 108020001507 fusion proteins Proteins 0.000 claims description 15
- 102000037865 fusion proteins Human genes 0.000 claims description 15
- 102000004169 proteins and genes Human genes 0.000 claims description 15
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 14
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 14
- 230000002441 reversible effect Effects 0.000 claims description 14
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 14
- 101150084750 1 gene Proteins 0.000 claims description 13
- 108091070501 miRNA Proteins 0.000 claims description 13
- 230000014509 gene expression Effects 0.000 claims description 12
- 239000002679 microRNA Substances 0.000 claims description 12
- 108020005029 5' Flanking Region Proteins 0.000 claims description 10
- 241000702421 Dependoparvovirus Species 0.000 claims description 10
- 230000000692 anti-sense effect Effects 0.000 claims description 10
- 108020004707 nucleic acids Proteins 0.000 claims description 10
- 102000039446 nucleic acids Human genes 0.000 claims description 10
- 150000007523 nucleic acids Chemical class 0.000 claims description 10
- 108091027967 Small hairpin RNA Proteins 0.000 claims description 8
- 239000004055 small Interfering RNA Substances 0.000 claims description 8
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims description 7
- 210000004185 liver Anatomy 0.000 claims description 7
- 238000010253 intravenous injection Methods 0.000 claims description 6
- 108020005065 3' Flanking Region Proteins 0.000 claims description 5
- 241000124008 Mammalia Species 0.000 claims description 3
- 101710117064 Trimethylamine corrinoid protein 1 Proteins 0.000 claims description 3
- 238000010255 intramuscular injection Methods 0.000 claims description 3
- 239000007927 intramuscular injection Substances 0.000 claims description 3
- 238000010254 subcutaneous injection Methods 0.000 claims description 3
- 239000007929 subcutaneous injection Substances 0.000 claims description 3
- 239000002131 composite material Substances 0.000 abstract description 11
- 230000008901 benefit Effects 0.000 abstract description 2
- 238000001727 in vivo Methods 0.000 description 27
- 230000000694 effects Effects 0.000 description 26
- 229940079593 drug Drugs 0.000 description 21
- 230000004048 modification Effects 0.000 description 21
- 238000012986 modification Methods 0.000 description 21
- 238000001338 self-assembly Methods 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 13
- 241000701161 unidentified adenovirus Species 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 11
- 102000004196 processed proteins & peptides Human genes 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 108020004999 messenger RNA Proteins 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 239000002250 absorbent Substances 0.000 description 8
- 230000002745 absorbent Effects 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 229920001184 polypeptide Polymers 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 102000008186 Collagen Human genes 0.000 description 6
- 108010035532 Collagen Proteins 0.000 description 6
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 6
- 241000713666 Lentivirus Species 0.000 description 6
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 6
- 125000000129 anionic group Chemical group 0.000 description 6
- 229920001436 collagen Polymers 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 6
- 239000000975 dye Substances 0.000 description 6
- 230000009368 gene silencing by RNA Effects 0.000 description 6
- 229960002591 hydroxyproline Drugs 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 6
- -1 Methoxyethyl Chemical group 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 108091062762 miR-21 stem-loop Proteins 0.000 description 4
- 108091041631 miR-21-1 stem-loop Proteins 0.000 description 4
- 108091044442 miR-21-2 stem-loop Proteins 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 101001087394 Homo sapiens Tyrosine-protein phosphatase non-receptor type 1 Proteins 0.000 description 3
- 102100033001 Tyrosine-protein phosphatase non-receptor type 1 Human genes 0.000 description 3
- 210000000805 cytoplasm Anatomy 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000008105 immune reaction Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 210000005228 liver tissue Anatomy 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 210000003712 lysosome Anatomy 0.000 description 3
- 230000001868 lysosomic effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 210000001087 myotubule Anatomy 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- DHRLEVQXOMLTIM-UHFFFAOYSA-N phosphoric acid;trioxomolybdenum Chemical compound O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.OP(O)(O)=O DHRLEVQXOMLTIM-UHFFFAOYSA-N 0.000 description 3
- 210000003370 receptor cell Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- WAVYAFBQOXCGSZ-UHFFFAOYSA-N 2-fluoropyrimidine Chemical compound FC1=NC=CC=N1 WAVYAFBQOXCGSZ-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 108091093037 Peptide nucleic acid Proteins 0.000 description 2
- 102000006382 Ribonucleases Human genes 0.000 description 2
- 108010083644 Ribonucleases Proteins 0.000 description 2
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 2
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 2
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 2
- RZUBARUFLYGOGC-MTHOTQAESA-L acid fuchsin Chemical compound [Na+].[Na+].[O-]S(=O)(=O)C1=C(N)C(C)=CC(C(=C\2C=C(C(=[NH2+])C=C/2)S([O-])(=O)=O)\C=2C=C(C(N)=CC=2)S([O-])(=O)=O)=C1 RZUBARUFLYGOGC-MTHOTQAESA-L 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 229960001506 brilliant green Drugs 0.000 description 2
- HXCILVUBKWANLN-UHFFFAOYSA-N brilliant green cation Chemical compound C1=CC(N(CC)CC)=CC=C1C(C=1C=CC=CC=1)=C1C=CC(=[N+](CC)CC)C=C1 HXCILVUBKWANLN-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000002719 pyrimidine nucleotide Substances 0.000 description 2
- 150000003230 pyrimidines Chemical class 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000012827 research and development Methods 0.000 description 2
- 230000004202 respiratory function Effects 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- XOSXWYQMOYSSKB-LDKJGXKFSA-L water blue Chemical compound CC1=CC(/C(\C(C=C2)=CC=C2NC(C=C2)=CC=C2S([O-])(=O)=O)=C(\C=C2)/C=C/C\2=N\C(C=C2)=CC=C2S([O-])(=O)=O)=CC(S(O)(=O)=O)=C1N.[Na+].[Na+] XOSXWYQMOYSSKB-LDKJGXKFSA-L 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- 108020004463 18S ribosomal RNA Proteins 0.000 description 1
- YYYARFHFWYKNLF-UHFFFAOYSA-N 4-[(2,4-dimethylphenyl)diazenyl]-3-hydroxynaphthalene-2,7-disulfonic acid Chemical compound CC1=CC(C)=CC=C1N=NC1=C(O)C(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=C12 YYYARFHFWYKNLF-UHFFFAOYSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 101150062301 Ddr2 gene Proteins 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 1
- 208000004852 Lung Injury Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 206010069363 Traumatic lung injury Diseases 0.000 description 1
- 108091026822 U6 spliceosomal RNA Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 125000005600 alkyl phosphonate group Chemical group 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 101150077855 arpc4 gene Proteins 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229920006317 cationic polymer Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 238000001553 co-assembly Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000008393 encapsulating agent Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002327 eosinophilic effect Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000009851 immunogenic response Effects 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 1
- 231100000515 lung injury Toxicity 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 108091027943 miR-16 stem-loop Proteins 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 230000036573 scar formation Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Abstract
The present application provides an RNA delivery system for the treatment of pulmonary fibrosis. The system comprises a viral vector, wherein the viral vector carries RNA segments capable of treating pulmonary fibrosis, the viral vector can be enriched in organ tissues of a host, and endogenously and spontaneously forms a composite structure containing the RNA segments capable of treating pulmonary fibrosis in the organ tissues of the host, and the composite structure can deliver the RNA segments to the lung to realize the treatment of pulmonary fibrosis. The safety and reliability of the RNA delivery system for treating pulmonary fibrosis are fully verified, the medicine property is very good, the universality is strong, and the economic benefit and the application prospect are excellent.
Description
Technical Field
The application relates to the technical field of biomedicine, in particular to an RNA delivery system for treating pulmonary fibrosis.
Background
Pulmonary fibrosis is the terminal change of a large group of lung diseases characterized by fibroblast proliferation and massive extracellular matrix aggregation with inflammatory injury and tissue structure destruction, namely structural abnormality (scar formation) caused by abnormal repair after normal alveolar tissues are damaged. Pulmonary fibrosis seriously affects the respiratory function of the human body, manifested as dry cough and progressive dyspnea (insufficient conscious qi), and the respiratory function of the patient is continuously worsened with the aggravation of the disease condition and the lung injury. The incidence and mortality of idiopathic pulmonary fibrosis increases year by year, with an average survival period of only 2.8 years after diagnosis, with mortality rates higher than that of most tumors, known as a "neoplastic-like disease".
RNA interference (RNAi) therapy has been considered a promising strategy for the treatment of human diseases since its invention, but in clinical practice a number of problems have been encountered, the progress of which has fallen far behind expectations.
It is generally considered that RNA cannot exist stably for a long period outside the cell because RNA is degraded into fragments by RNase which is abundantly present outside the cell, therefore, it is necessary to find a method for stably presenting RNA outside cells and targeting RNA into specific tissues, so as to highlight the effect of RNAi therapy.
Many patents related to siRNA are focused on the following aspects: 1. siRNA with medical effect is designed. 2. The siRNA is chemically modified, so that the stability of the siRNA in an organism is improved, and the yield is improved. 3. Various artificial carriers (such as lipid nanoparticles, cationic polymers and viruses) are designed to improve the efficiency of siRNA delivery in vivo. Among them, the patent of the 3 rd aspect is many, and the root cause thereof is that researchers have recognized that there is a lack of suitable siRNA delivery system for delivering siRNA to target tissues safely, accurately and efficiently, which has become a core problem that restricts RNAi therapy.
A virus (Biological virus) is a noncellular organism which is small in size, simple in structure, contains only one nucleic acid (DNA or RNA), and must be parasitic in living cells and proliferated in a replicative manner. Viral vectors can bring genetic material into cells, and the principle is that viruses have a molecular mechanism of transmitting their genomes into other cells for infection, can occur in whole living organisms (in vivo) or in cell culture (in vitro), and are mainly applied to basic research, gene therapy or vaccines. However, there are currently few studies related to the use of viruses as vectors for the delivery of RNA, in particular siRNA, using specific self-assembly mechanisms.
Chinese patent with publication number CN108624590A discloses a siRNA capable of inhibiting DDR2 gene expression; chinese patent with publication number CN108624591A discloses a siRNA capable of silencing ARPC4 gene, and the siRNA is modified by alpha-phosphorus-selenium; chinese patent with publication number CN108546702A discloses siRNA of targeting long-chain non-coding RNA DDX11-AS 1. Chinese patent publication No. CN106177990A discloses a siRNA precursor that can be used for various tumor treatments. These patents have designed specific sirnas and are directed to certain diseases caused by genetic changes.
Chinese patent publication No. CN108250267A discloses a polypeptide, polypeptide-siRNA induced co-assembly, using polypeptide as a carrier of si RNA. Chinese patent publication No. CN108117585A discloses a polypeptide for promoting breast cancer apoptosis by targeted introduction of siRNA, and also uses the polypeptide as a carrier of siRNA. Chinese patent publication No. CN108096583A discloses a nanoparticle carrier, which can contain chemotherapeutic drugs and also can be loaded with siRNA with breast cancer therapeutic effect. These patents are all inventions in the aspect of siRNA vector, but the technical scheme has a common feature that the vector and siRNA are pre-assembled in vitro and then introduced into the host. In fact, most of the delivery technologies designed today are so. However, such delivery systems have a common problem in that these artificially synthesized exogenous delivery systems are easily cleared by the host's circulatory system, may elicit an immunogenic response, and may even be toxic to specific cell types and tissues.
The research team of the present invention finds that endogenous cells can selectively encapsulate miRNAs into exosomes (exosomes) which can deliver miRNAs into recipient cells, and the secreted miRNAs can powerfully block the expression of target genes at relatively low concentrations. Exosomes are biocompatible with the host immune system and have the innate ability to protect and transport miRNA across biological barriers in vivo, thus becoming a potential solution to overcome problems associated with siRNA delivery. For example, chinese patent publication No. CN110699382A discloses a method for preparing exosomes for delivering siRNA, and discloses a technique for isolating exosomes from plasma and encapsulating siRNA into exosomes by electroporation.
However, such technologies for in vitro separation or preparation of exosomes usually require a large amount of exosomes obtained by cell culture, and a step of sirna encapsulation, which causes the clinical cost of large-scale application of the product to be very high and cannot be borne by general patients; more importantly, the complex production/purification process of exosomes makes it almost impossible to comply with GMP standards.
The drug taking exosome as an active ingredient has not been approved by CFDA so far, and the core problem is that the consistency of exosome products cannot be ensured, and the problem directly results in that the products cannot obtain the drug production license. If this problem can be solved, it would be of no great significance to driving RNAi therapy for pulmonary fibrosis.
Therefore, the development of a safe, accurate and efficient siRNA delivery system is a crucial link for improving the RNAi therapeutic effect of pulmonary fibrosis and promoting RN Ai therapy.
Disclosure of Invention
In view of the above, the present embodiments provide an RNA delivery system for treating pulmonary fibrosis, so as to solve the technical deficiencies in the prior art.
One aspect of the present application is to provide an RNA delivery system for treating pulmonary fibrosis, which includes a viral vector carrying RNA fragments capable of treating pulmonary fibrosis, wherein the viral vector can be enriched in organ tissues of a host, and endogenously and spontaneously forms a composite structure containing the RNA fragments capable of treating pulmonary fibrosis in the organ tissues of the host, and the composite structure can deliver the RNA fragments into the lung to treat pulmonary fibrosis. After the RNA segment is sent into the target tissue lung, the expression of the gene matched with the RNA segment can be inhibited, and further the development of pulmonary fibrosis is inhibited.
Further, the viral vector is an adeno-associated virus.
Further, the adenovirus-associated virus is adenovirus-associated virus type 5, adenovirus-associated virus type 8 or adenovirus-associated virus type 9.
Further, the RNA fragment comprises 1, two or more specific RNA sequences of medical significance, which are siRNA, shRNA or miRNA of medical significance.
Further, the viral vector comprises a promoter and a targeting tag, wherein the targeting tag is capable of forming a targeting structure of the complex structure in an organ tissue of a host, the targeting structure is positioned on the surface of the complex structure, and the complex structure is capable of searching for and binding to a target tissue through the targeting structure to deliver the RNA segment into the target tissue.
Further, the virus vector comprises any one line or combination of lines of the following: promoter-RNA fragment, promoter-targeting tag, promoter-RNA fragment-targeting tag; each viral vector comprises at least one RNA segment and one targeting label, wherein the RNA segment and the targeting label are positioned in the same line or different lines.
Further, the viral vector further comprises flanking sequences, including 5 'flanking sequences and 3' flanking sequences, compensating sequences and a loo p sequence, which enable the lines to be folded into correct structure and expressed;
the virus vector comprises any one line or combination of several lines: 5 '-promoter-5' flanking sequence-RNA fragment-loop sequence-compensating sequence-3 'flanking sequence, 5' -promoter-targeting label-5 'flanking sequence-RNA fragment-loop sequence-compensating sequence-3' flanking sequence.
Further, the 5' flanking sequence is ggatcctggaggcttgctgaaggctgtatgctgaattc or a sequence having more than 80% homology thereto;
the loop sequence is gtttggccactgactgac or a sequence with homology more than 80 percent;
<xnotran> 3' accggtcaggacacaaggcctgttactagcactcacatggaacaaatggcccagatctggccgcactcgag 80% ; </xnotran>
The compensation sequence is a reverse complementary sequence of the RNA segment, and any 1-5 bases in the RNA segment are deleted. The order of deletion of the 1-5 bases of the reverse complement of RNA is such that the sequence is not expressed.
Preferably, the complementing sequence is a reverse complement of the RNA fragment, and any 1-3 bases in the complementing sequence are deleted.
More preferably, the complementary sequence is the reverse complement of the RNA fragment, and any 1-3 consecutive bases in the complementary sequence are deleted.
Most preferably, the complementing sequence is the reverse complement of the RNA fragment, and the 9 th and/or 10 th base is deleted.
Further, in the case where at least two kinds of strands are present in the viral vector, adjacent strands are connected to each other by a sequence consisting of sequences 1 to 3 (sequence 1-sequence 2-sequence 3);
wherein, the sequence 1 is CAGATC, the sequence 2 is a sequence consisting of 5-80 bases, and the sequence 3 is TGGATC.
Further, in the case where at least two kinds of lanes are present in the viral vector, adjacent lanes are connected to each other through sequence 4 or a sequence having a homology of more than 80% to sequence 4;
wherein the sequence 4 is CAGATCTGGCCGCACTCGAGGTAGTGAGTCGACGACCAGTGGAC.
Further, the organ tissue is a liver, and the composite structure is an exosome.
Further, the targeting label is selected from targeting peptides or targeting proteins with targeting functions.
Further, the targeting peptides include RVG targeting peptide, GE11 targeting peptide, PTP targeting peptide, TCP-1 targeting peptide, MSP targeting peptide;
the target protein comprises RVG-LAMP2B fusion protein, GE11-LAMP2B fusion protein, PTP-LAMP2B fusion protein, TCP-1-LAMP2B fusion protein and MSP-LAMP2B fusion protein.
Further, the RNA sequence is 15-25 nucleotides in length. For example, the RNA sequence may be 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 nucleotides in length. Preferably, the RNA sequence is 18-22 nucleotides in length.
Further, the RNA capable of treating pulmonary fibrosis is selected from any one or more of the following RNAs: an antisense strand of miRNA-21, an siRNA of a TGF-beta 1 gene, or an RNA sequence having greater than 80% homology with the above sequence, or a nucleic acid molecule encoding the above RNA. It should be noted that the RNA sequence in the "nucleic acid molecule encoding the RNA sequence" also includes RNA sequences having a homology of more than 80% for each RNA.
The siRNA of TGF-beta 1 gene comprises ACGGAAAUAACCUAGAGUGGGC, UGAACUUGUCAUAGAUUUCGUCU, UUGAACAUAUAUAUAUGCUG, UCUAACCACAGUGUGUUCCC, UCUCAGACUCUGGGGCCUCAG, other sequences which can inhibit the expression of TGF-beta 1 gene and sequences with homology more than 80 percent with the sequences.
The antisense strand of miRNA-21 is 5.
The "sequence having a homology of more than 80%" as described above may be 85%, 88%, 90%, 95%, 98%, etc.
Optionally, the RNA fragment comprises an RNA sequence body and a modified RNA sequence obtained by ribose modification of the RNA sequence body. That is, the RNA fragment may consist of only at least one RNA sequence entity, may consist of only at least one modified RNA sequence, or may consist of both the RNA sequence entity and the modified RNA sequence.
In the present invention, the isolated nucleic acids also include variants and derivatives thereof. The nucleic acids can be modified by one of ordinary skill in the art using conventional methods. Modifications include (but are not limited to): methylation modification, alkyl modification, glycosylation modification (such as 2-methoxy-glycosyl modification, alkyl-glycosyl modification, sugar ring modification and the like), nucleic acid modification, peptide segment modification, lipid modification, halogen modification, nucleic acid modification (such as 'TT' modification) and the like. In one embodiment of the invention, the modification is an internucleotide linkage, for example selected from: thiophosphate, 2'-O Methoxyethyl (MOE), 2' -fluoro, alkyl phosphonate, dithiophosphate, alkyl thiophosphonate, phosphoramidate, carbamate, carbonate, phosphotriester, acetamide ester, carboxymethyl ester, and combinations thereof. In one embodiment of the invention, the modification is a modification to a nucleotide, for example selected from: peptide Nucleic Acids (PNA), locked Nucleic Acids (LNA), arabinose-nucleic acids (FANA), analogs, derivatives, and combinations thereof. Preferably, the modification is a 2' fluoropyrimidine modification. The 2 '-fluoropyrimidine modification is to replace 2' -OH of pyrimidine nucleotide on RNA with 2'-F, and the 2' -F can make RNA not be easily recognized by RNase in vivo, thereby increasing the stability of RNA fragment in vivo delivery.
Further, the delivery system is a delivery system for use in mammals including humans.
Another aspect of the present application is to provide a use of the RNA delivery system for the treatment of pulmonary fibrosis as described above in medicine.
The drug comprises the viral vector, specifically, the viral vector is a viral vector carrying an RNA fragment or carrying an RNA fragment and a targeting tag, and can enter a host body to be enriched at a liver part and self-assemble to form a composite structure exosome, and the composite structure can deliver the RNA fragment to a target tissue to enable the RNA fragment to be expressed in the target tissue, so that the expression of a gene matched with the RNA fragment is inhibited, and the purpose of treating diseases is achieved.
Furthermore, the drug is a drug for treating pulmonary fibrosis and related diseases thereof, wherein the related diseases refer to related diseases or complications, sequelae and the like occurring in the formation or development process of the pulmonary fibrosis, or other diseases having a certain correlation with pulmonary fibrosis.
Further, the administration mode of the medicine comprises oral administration, inhalation, subcutaneous injection, intramuscular injection and intravenous injection.
The dosage form of the medicine can be tablets, capsules, powder, granules, pills, suppositories, ointments, solutions, suspensions, lotions, gels, pastes and the like.
The technical effects of this application do:
the RNA delivery system for treating pulmonary fibrosis provided by the application takes the virus as a vector, and the virus vector is taken as a mature injectant, so that the safety and reliability of the RNA delivery system are fully verified, and the RNA delivery system is very good in drug property. The RNA sequence which finally exerts the effect is wrapped and conveyed by the endogenous exosome, no immune reaction exists, and the safety of the exosome does not need to be verified. The delivery system can deliver various small-molecule RNAs and has strong universality. And the preparation of the virus vector is cheaper than that of exosome or substances such as protein, polypeptide and the like, and the economy is good. The RNA delivery systems provided herein are capable of self-assembly with an AGO in vivo 2 Tightly bound and enriched in a complex structure (exosome) not only preventing its premature degradation, maintaining it in circulationThe stability of the composition is favorable for the absorption of receptor cells, the intracytoplasmic release and the escape of lysosomes, and the required dosage is low.
The RNA delivery system for treating pulmonary fibrosis, provided by the application, is applied to medicines, namely, a medicine delivery platform is provided, the treatment effect of pulmonary fibrosis can be greatly improved, the research and development basis of more RNA medicines can be formed through the platform, and great promotion effect is achieved on research and development and use of RNA medicines.
Drawings
FIG. 1 is a graph comparing the hydroxyproline content and mRNA levels in mice provided in an example of the present application;
FIG. 2 is a Masson trichrome staining of mouse lungs as provided in an example of the present application.
FIG. 3 is a graph showing the enrichment in vivo, self-assembly and pulmonary fibrosis treatment effects of the present application when loaded with RNA fragments using adenovirus and lentivirus as viral vectors, wherein the viral vectors are adenovirus/lentivirus, and the enrichment results are shown in terms of siRNA content, in which A is an enrichment map in the lung after injection of the delivery system (siRNA-1), B is an enrichment map in the lung after injection of the delivery system (SiRN A-2), C is an enrichment map in the blood after injection of the delivery system (siRNA-1), and D is an enrichment map in the blood after injection of the delivery system (siRNA-2).
Fig. 4 is a graph of the detection of the effect of in vivo enrichment, self-assembly and pulmonary fibrosis treatment when loading RNA fragments with adenovirus and lentivirus as viral vectors, wherein the viral vectors are adenovirus/lentivirus, the enrichment results are shown by siRNA content, in which a is an enrichment map in the lung after injection of the delivery system without targeting peptide (GE 11), B is an enrichment map in the lung after injection of the delivery system with targeting peptide (GE 11), C is an enrichment map in the blood after injection of the delivery system without targeting peptide (GE 11) (siRNA-1), and D is an enrichment map in the blood after injection of the delivery system with targeting peptide (GE 11) (siRNA-2).
Fig. 5 shows the results of in vivo enrichment, self-assembly and detection of the therapeutic effect on pulmonary fibrosis under the condition that a viral vector system provided in an embodiment of the present application carries a plurality of different RNA fragments, where a is the result of detection of the relative amount of mRNA of PTP1B, and B is the result of detection of the relative amount of protein of PTP 1B.
FIG. 6 is a graph showing the results of in vivo enrichment, self-assembly and therapeutic effect of pulmonary fibrosis after intravenous injection when a viral vector delivery system provided in an embodiment of the present application comprises multiple RNA fragments and multiple targeting tags (CMV-siRNA-1 + 2), where A is the enrichment effect in lung (shown by siRNA content) and B is the enrichment effect in blood (shown by siRNA content).
FIG. 7 shows the results of in vivo enrichment, self-assembly and therapeutic effect of pulmonary fibrosis after intravenous injection when a viral vector delivery system provided in another embodiment of the present application comprises a plurality of RNA fragments and a plurality of targeting tags (CMV-GE 11-siRNA-1+2, CMV-GE11-siRNA-1+ CMV-GE 11-siRNA-2), wherein A and B are the enrichment effect in lung (shown by siRNA content) and C and D are the enrichment effect in plasma (shown by siRNA content).
FIG. 8 shows the result of detecting the therapeutic effect of pulmonary fibrosis after intravenous injection when a viral vector delivery system provided in yet another embodiment of the present application comprises a plurality of RNA fragments and a plurality of targeting tags (CMV-GE 11-siRNA-1+2, CMV-GE11-siRNA-1+ CMV-GE 11-siRNA-2), where A and B are the result of detecting the protein content of TGFb1 and C and D are the result of detecting the mRNA content of TGFb 1.
FIG. 9 is a graph showing the results of in vivo enrichment test (indicated by siRNA content in blood) when the adenovirus vector delivery system provided in one embodiment of the present application comprises 35 'flanking sequences/loop sequences/3' flanking sequences having a homology of greater than 80%.
FIG. 10 is a graph showing the results of in vivo enrichment detection (indicated by siRNA content in blood) of delivery systems constructed when a plurality of lines are carried by an adenoviral vector provided in one embodiment of the present application, and the adjacent lines are connected by the sequences 1-sequence 2-sequence 3, wherein sequence 2 comprises a plurality of bases.
FIG. 11 is a graph showing the results of in vivo enrichment of the delivery system constructed by the ligation sequence provided in one embodiment of the present application as SEQ ID No. 4 and a sequence having more than 80% homology to SEQ ID No. 4 (indicated by siRNA content in blood).
Fig. 12 is a graph showing the results of detecting the therapeutic effect of pulmonary fibrosis by the delivery system constructed when the lengths of the RNA sequences are 18, 20, and 21, respectively, in which a is the result of detecting the relative amount of PTP1B mRNA of RNA sequences of different lengths, and B is the result of detecting the relative amount of PTP1B protein of RNA sequences of different lengths.
FIG. 13 shows the hydroxyproline content detected by the gene circuit provided in an embodiment of the present application under the condition of including the antisense strand of miRNA-21 and 5 pieces of TGF-beta 1 gene siRNA.
Detailed Description
The following description of specific embodiments of the present application refers to the accompanying drawings.
Masson staining gives collagen fibers a blue (stained by aniline blue) or green (stained by brilliant green) color and muscle fibers a red (stained by acid fuchsin and ponceau red) color, depending on the size of the anionic dye molecules and the permeability of the tissue. Fixed tissue is stained with a series of anionic water-soluble dyes, either sequentially or in combination, and it is found that red blood cells are stained with the smallest anionic dye, muscle fibers and cytoplasm are stained with the medium-sized anionic dye, and collagen fibers are stained with the larger anionic dye. This demonstrates that the permeability of erythrocytes to anionic dyes is minimal, the muscle fibers are inferior to the cytoplasm, and collagen fibers have the greatest permeability. Type I and type III collagens are green (GBM, TBM, mesangial matrix and renal interstitium are green), and the eosinophilic proteins, tubule cytoplasm, and erythrocytes are red.
The Masson staining method specifically comprises the following steps:
fixing the tissue in Bouin's fluid, flushing with running water for one night, and conventionally dehydrating and embedding; slicing and dewaxing to water (dewaxing in xylene for 10min × 3 times, sucking liquid with absorbent paper, sucking liquid with 100% ethanol for 5min × 2 times, sucking liquid with absorbent paper, sucking liquid with 95% ethanol for 5min × 2 times, sucking liquid with absorbent paper, flowing water for 2min, sucking water with absorbent paper); weiger's ferrohematoxylin staining for 5-10min; slightly washing with running water; differentiating with 0.5% hydrochloric acid alcohol for 15s; flushing with running water for 3min; dyeing the ponceau acid fuchsin liquid for 8min; slightly washing with distilled water; treating with 1% phosphomolybdic acid water solution for about 5min; directly re-dyeing with aniline blue solution or brilliant green solution for 5min without washing with water; treating with 1% glacial acetic acid for 1min; dehydrating with 95% ethanol for 5min × 2 times, and drying with absorbent paper; 100% ethanol for 5min × 2 times, and drying the liquid with absorbent paper; transparent in xylene for 5min × 2 times, and sucking the liquid with absorbent paper; and (5) sealing the neutral gum.
The detection of siRNA level, protein content and mRNA content in the invention is realized by injecting RNA delivery system into mouse body to establish mouse stem cell in vitro model. mRNA and siRNA expression levels in cells and tissues were examined by qRT-PCR. The absolute quantification of siRNA was determined by plotting a standard curve against the standard. The expression amount of each siRNA or mRNA relative to the internal reference can be expressed by 2- Δ CT, where Δ CT = C sample-C internal reference. The internal reference gene is U6 snRNA (in tissues) or miR-16 (in serum and exosomes) molecules when siRNA is amplified, and the time base of mRNA is GAPDH or 18s RNA. And detecting the expression level of the protein in the cells and tissues by using a Western blotting experiment, and carrying out protein quantitative analysis by using ImageJ software.
In the illustrations provided herein, "+" indicates P <0.05, "+" indicates P <0.01, and "+" indicates P <0.005.
In the present invention, unless otherwise specified, scientific and technical terms used herein have the meanings commonly understood by those skilled in the art. Also, the reagents, materials and procedures used herein are those that are widely used in the corresponding fields.
Example 1
The present embodiment provides an RNA delivery system for treating pulmonary fibrosis, comprising a viral vector carrying RNA fragments capable of treating pulmonary fibrosis, wherein the viral vector is capable of being enriched in organ tissues of a host and endogenously and spontaneously forming a complex structure containing the RNA fragments capable of treating pulmonary fibrosis in the organ tissues of the host, and the complex structure is capable of delivering the RNA fragments into the lung to achieve the treatment of pulmonary fibrosis.
When the adenovirus and the lentivirus are used as viral vectors and loaded with RNA fragments, whether the RNA fragments are provided with targeting labels or not, the adenovirus and the lentivirus have in vivo enrichment, self-assembly and pulmonary fibrosis treatment effects, and the enrichment effect is shown by the siRNA content in lung and blood as shown in figures 3-4.
In this embodiment, the viral vector further comprises a promoter and a targeting tag. The virus vector comprises any one line or combination of lines of: the virus vector comprises a promoter-RNA sequence, a promoter-targeting label and a promoter-RNA sequence-targeting label, wherein each virus vector at least comprises an RNA segment and a targeting label, and the RNA segment and the targeting label are positioned in the same line or different lines. In other words, the viral vector may include only the promoter-RNA sequence-targeting tag, or may include a combination of the promoter-RNA sequence, the promoter-targeting tag, or a combination of the promoter-targeting tag and the promoter-RNA sequence-targeting tag.
When the viral vector delivery system comprises a plurality of RNA fragments and a plurality of targeting tags, the viral vector delivery system has the effects of in vivo enrichment, self-assembly and pulmonary fibrosis treatment, as shown in fig. 6-8, wherein the targeting tag is GE11, and the RNA fragments are siRNA-1, siRNA-2 and siRNA-1+ siRNA-2.
Further, the viral vector may further comprise flanking sequences, including 5 'flanking sequences and 3' flanking sequences, which enable the lines to be folded into the correct structure and expressed, compensating sequences and loop sequences; the virus vector comprises any one line or combination of lines of: 5 '-promoter-5' flanking sequence-RNA fragment-loop sequence-compensating sequence-3 'flanking sequence, 5' -promoter-targeting label-5 'flanking sequence-RNA fragment-loop sequence-compensating sequence-3' flanking sequence.
Wherein, the 5' flanking sequence is preferably ggatcctggaggcttgctgtgagaggctgtatgctgaattgaattc or a sequence with homology of more than 80 percent with the ggatcctggaggcttgctgagagctgctgtatgctgaattc, including sequences with homology of 85 percent, 90 percent, 92 percent, 95 percent, 98 percent, 99 percent and the like.
The loop sequence is preferably gttttgggccactgactgac or a sequence with homology of more than 80 percent, and comprises sequences with homology of 85 percent, 90 percent, 92 percent, 95 percent, 98 percent, 99 percent and the like with the gtttggccactgactgac.
<xnotran> 3' accggtcaggacacaaggcctgttactagcactcacatggaacaaatggcccagatctggccgcactcgag 80% , accggtcaggacacaaggcctgttactagcactcacatggaacaaatggcccagatctggccgcactcgag 85%, 90%, 92%, 95%, 98%, 99% . </xnotran>
The compensation sequence is a reverse complementary sequence of the RNA segment, and any 1-5 bases in the RNA segment are deleted. When the RNA fragment contains only one RNA sequence, the complementary sequence may be a reverse complement of the RNA sequence in which any 1-5 bases are deleted.
Preferably, the complementing sequence is the reverse complement of the RNA fragment, and any 1-3 bases in the RNA fragment are deleted. When the RNA fragment contains only one RNA sequence, the complementary sequence may be a reverse complement of the RNA sequence from which any 1 to 3 bases are deleted.
More preferably, the complementary sequence is the reverse complement of the RNA fragment, and any 1-3 consecutive bases in the complementary sequence are deleted. When the RNA fragment contains only one RNA sequence, the complementary sequence may be a reverse complement of the RNA sequence from which any of the bases arranged consecutively at positions 1 to 3 are deleted.
Most preferably, the complementing sequence is the reverse complement of the RNA fragment, and the 9 th and/or 10 th base is deleted. When only one RNA sequence is included in the RNA fragment, the complementing sequence may be a reverse complement of the RNA sequence from which the 9 th and/or 10 th position is deleted. The deletion of the 9 th and 10 th bases is most effective.
The flanking sequence, the compensating sequence and the loop sequence are not randomly selected, but are determined based on a large amount of theoretical research and experiments, and the expression rate of the RNA fragment can be improved to the maximum extent under the coordination of the specific flanking sequence, the compensating sequence and the loop sequence.
The adenovirus vector also has in vivo enrichment, self-assembly and therapeutic effect on pulmonary fibrosis in the case of containing 3 homologous sequences, as shown in fig. 9, the sequences are grouped as follows:
1. 3 5' flanking sequences with homology of more than 80%;
2. 3 loop sequences with homology more than 80%;
3. 3' flanking sequences with homology greater than 80%.
The sequence is shown in Table 2 below.
In the case of viral vectors carrying two or more strands, adjacent strands may be connected by sequence 1-sequence 2-sequence 3; among them, the sequence 1 is preferably CAGATC, the sequence 2 may be a sequence consisting of 5 to 80 bases, such as 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75 bases, preferably a sequence consisting of 10 to 50 bases, more preferably a sequence consisting of 20 to 40 bases, and the sequence 3 is preferably TGGATC.
When the adenovirus vector carries a plurality of lines, adjacent lines are connected by a sequence 1-a sequence 2-a sequence 3, wherein the sequence 2 contains a plurality of bases, and the constructed delivery system also has the effects of in vivo enrichment, self-assembly and pulmonary fibrosis treatment, as shown in figure 10.
More preferably, in the case of a viral vector carrying two or more strands, adjacent strands are connected to each other via sequence 4 or a sequence having a homology of greater than 80% to sequence 4; wherein the sequence 4 is CAGATCTGGCCGCACTCGAGGTAGTGAGTCGACGACCAGTGGAC.
When the connecting sequence is the sequence 4 and the sequence with homology more than 80% with the sequence 4, the constructed delivery system also has in vivo enrichment, self-assembly and pulmonary fibrosis treatment effects, as shown in fig. 11, the sequence 4-1 in fig. 11 is the sequence 4, the sequences 4-2/4-3/4-4 are homologous sequences of the sequence 4-1 respectively, and the sequences are specifically shown in the following table 4.
| Sequence 4-1 | CAGATCTGGCCGCACTCGAGGTAGTGAGTCGACCAGTGGATC |
| Sequence 4-2 | CAGATCTGGCCGCACTCGTAGAGGTGAGTCGACCAGTGGATC |
| Sequence 4-3 | CAGATCTGGCACCCGTCGAGGTAGTGAGTCGACCAGTGGATC |
| Sequence 4-4 | CAGATCTGGCCGCACAGGTCGTAGTGAGTCGACCAGTGGATC |
The RNA fragments described above comprise 1, two or more specific RNA sequences of medical interest, which are capable of being expressed in the target receptor and the complementing sequences are not capable of being expressed in the target receptor. The RNA sequence can be an siRNA sequence, an shRNA sequence or an miRNA sequence, and is preferably an siRNA sequence.
An RNA sequence is 15-25 nucleotides (nt), preferably 18-22nt, such as 18nt, 19nt, 20nt, 21nt, 22 nt. The range of the sequence length is not arbitrarily selected, but determined by trial and error. A large number of experiments prove that under the condition that the length of the RNA sequence is less than 18nt, particularly less than 15nt, the RNA sequence is mostly ineffective and can not play a role, and under the condition that the length of the RNA sequence is more than 22nt, particularly more than 25nt, the cost of a line is greatly improved, the effect is not better than that of the RNA sequence with the length of 18-22nt, and the economic benefit is poor. Therefore, when the length of the RNA sequence is 15 to 25nt, particularly 18 to 22nt, both cost and action can be achieved, and the effect is the best.
When the length of the RNA sequence is 18, 20 and 21 respectively, the constructed delivery system also has the treatment effects of in vivo enrichment, self-assembly and pulmonary fibrosis, as shown in figure 12, and the specific sequence is shown in table 5.
| 21nt sequence | TATCTTTGCTGTCACAAGAGC |
| 19nt sequence | TAAAGTCAATGTACAGCTG |
| 18nt sequence | TTCATGTCATGGATGGTG |
The RNA capable of treating pulmonary fibrosis is selected from any one or more of the following RNAs: an antisense strand of miRNA-21, an siRNA of TGF-. Beta.1 gene, or a nucleic acid molecule encoding the above RNA.
The siRNA of the TGF-beta 1 gene comprises ACGGAAAUAACCUAGAGUGGGC, UGAACUUGUCAUAGAUUUCGUCU, UUGAACAUAUAUAUAUGCUG, UCUAACUACAGUAGUGUUCCCC, UCUCUCAGACUCUGGGGCCUCAG, other sequences which can inhibit the expression of the TGF-beta 1 gene and sequences with homology of more than 80 percent with the sequences.
The antisense chain of miRNA-21 is 5 'and TCAACATCAGTCTGATAAGCTA-3'.
The gene circuit has the in vivo enrichment, self-assembly and pulmonary fibrosis treatment effects under the condition that the gene circuit comprises an miRNA-21 antisense chain and the 5 TGF-beta 1 gene siRNAs (siRNA-1, siRNA-2, siRNA-3, siRNA-4 and siRNA-5), as shown in figure 13.
The number of RNA effective sequences capable of treating pulmonary fibrosis is 1, 2 or more. For example, the siRNA of the miRNA-21 antisense strand or the TGF-beta 1 gene alone may be used on the same viral vector, or the siRNA of the miRNA-21 antisense strand and the TGF-beta 1 gene may be used in combination on the same viral vector.
Taking the combined use of "siRNA1" and "siRNA2" on the same viral vector as an example, the functional structural region of the viral vector can be represented as: (promoter-siRNA 1) -linker- (promoter-siRNA 2) -linker- (promoter-targeting tag), or (promoter-targeting tag-siRNA 1) -linker- (promoter-targeting tag-siRNA 2), or (promoter-siRNA 1) -linker- (promoter-targeting tag-siRNA 2), etc.
More specifically, the functional domains of the viral vector can be represented as: (5 ' -promoter-5 ' flanking sequence-siRNA 1-loop sequence-compensating sequence-3 ' flanking sequence) -linking sequence- (5 ' -promoter-5 ' flanking sequence-siRNA 2-loop sequence-compensating sequence-3 ' flanking sequence) -linking sequence- (5 ' -promoter-targeting tag) -5' flanking sequence-siRNA 1-loop sequence-compensating sequence-3 ' flanking sequence) -linking sequence- (5 ' -promoter-targeting tag-5 ' flanking sequence-siRNA 2-loop sequence-compensating sequence-3 ' flanking sequence), or (5 ' -promoter-5 ' flanking sequence-siRNA 1-loop sequence-compensating sequence-3 ' flanking sequence) -linking sequence- (5 ' -promoter-targeting tag-5 ' flanking sequence-siRNA 2-loop sequence-compensating sequence-3 ' flanking sequence), (5 ' -promoter-targeting tag-5 ' flanking sequence-1-siRNA 2-loop sequence-compensating sequence-3 ' flanking sequence), etc. In other cases, the same can be analogized, and the description is omitted here. The above linker sequence may be "sequence 1-sequence 2-sequence 3" or "sequence 4", and a bracket indicates a complete line (circuit).
Preferably, the RNA may be obtained by modifying RNA sequences (siRNA, shRNA, or miRNA) thereof with ribose, preferably 2' fluoropyrimidine. The 2 '-fluoropyrimidine modification is to replace 2' -OH of pyrimidine nucleotide on siRNA, shRNA or miRNA with 2'-F, wherein the 2' -F can make RNA enzyme in human body not easily recognize the siRNA, shRNA or miRNA, so that the stability of RNA in vivo transmission can be increased.
Specifically, the liver phagocytoses exogenous viruses, up to 99% of the exogenous viruses enter the liver, so that when the viruses are used as vectors, the viruses can be enriched in liver tissues without specific design, then the viral vectors are opened to release RNA molecules (siRNA, shRNA or miRNA), the liver tissues spontaneously wrap the RNA molecules into exosomes, and the exosomes become RNA delivery mechanisms.
Preferably, in order to make the RNA delivery mechanism (exosome) have the ability of "precise targeting", we design a targeting tag in the viral vector injected into the body, and the targeting tag will also be assembled into the exosome by the liver tissue, especially when selecting some specific targeting tags, the targeting tag can be inserted into the exosome surface, thereby becoming a targeting structure capable of guiding exosome, which greatly improves the accuracy of the RNA delivery mechanism of the present invention, on one hand, the amount of the viral vector to be introduced can be greatly reduced, and on the other hand, the efficiency of potential drug delivery can be greatly improved.
The targeting label is selected from one of peptides, proteins or antibodies with targeting functions, the selection of the targeting label is a process requiring creative labor, on one hand, an available targeting label needs to be selected according to target tissues, and on the other hand, the targeting label is ensured to be stably present on the surface of exosomes, so that the targeting function is achieved. Targeting tags that have been selected so far include: targeting peptides, targeting proteins, antibodies. Wherein, the targeting peptide includes but is not limited to RVG targeting peptide (the nucleotide sequence is shown in SEQ ID No: 1), GE11 targeting peptide (the nucleotide sequence is shown in SEQ ID No: 2), PTP targeting peptide (the nucleotide sequence is shown in SEQ ID No: 3), TCP-1 targeting peptide (the nucleotide sequence is shown in SEQ ID No: 4), MSP targeting peptide (the nucleotide sequence is shown in SEQ ID No: 5); the target protein includes, but is not limited to, RVG-LAMP2B fusion protein (nucleotide sequence is shown in SEQ ID No: 6), GE11-LAMP2B fusion protein (nucleotide sequence is shown in SEQ ID No: 7), PTP-LAMP2B fusion protein (nucleotide sequence is shown in SEQ ID No: 8), TCP-1-LAMP2B fusion protein (nucleotide sequence is shown in SEQ ID No: 9), MSP-LAMP2B fusion protein (nucleotide sequence is shown in SEQ ID No: 10).
Furthermore, for the purpose of precise delivery, we tested various viral vector loading schemes, and developed another optimized scheme: the viral vector may also be composed of multiple viruses with different structures, one virus containing a promoter and a targeting tag, and the other virus containing a promoter and an RNA fragment. The targeting effect of the two viral vectors is not inferior to that generated by loading the same targeting tag and RNA segment in one viral vector.
More preferably, when two different viral vectors are injected into a host, the viral vector with the RNA sequence can be injected first, and then the viral vector containing the targeting tag is injected after 1-2 hours, so that a better targeting effect can be achieved.
The delivery systems described above may be used in mammals including humans.
The RNA delivery system provided by the embodiment takes the virus as a vector and the viral vector as a mature injectant, the safety and reliability of the RNA delivery system are fully verified, and the RNA delivery system has very good druggability. The RNA sequence which finally exerts the effect is encapsulated and conveyed by the endogenous exosome, no immune reaction exists, and the safety of the exosome does not need to be verified. The delivery system can deliver various small-molecule RNAs and has strong universality. And the preparation of the virus vector is cheaper than that of exosome or substances such as protein, polypeptide and the like, and the economy is good. The RNA delivery systems provided herein are capable of self-assembly with an AGO in vivo 2 Tightly combined and enriched into a composite structure (exosome), not only can prevent the exosome from being prematurely degraded, but also can maintain the exosome inThe stability of the composition in the circulation of the composition, but also is beneficial to the absorption of receptor cells, the intracytoplasmic release and the escape of lysosomes, and the required dosage is low.
Example 2
On the basis of example 1, this example provides a drug. The drug comprises a viral vector, wherein the viral vector carries RNA segments capable of treating pulmonary fibrosis, the viral vector can be enriched in host organ tissues, and endogenously and spontaneously forms a composite structure containing the RNA segments capable of treating pulmonary fibrosis in the host organ tissues, and the composite structure can deliver the RNA segments to the lung to realize the treatment of pulmonary fibrosis.
Optionally, the RNA fragment comprises 1, two or more specific RNA sequences of medical interest, said RNA sequences being siRNA, shRNA or miRNA of medical interest.
In the case of viral vector system carrying multiple different RNA fragments, it has the effects of in vivo enrichment, self-assembly and treatment against pulmonary fibrosis, as shown in fig. 5, where the RNA fragments are grouped as follows:
1. 6 RNAs were used alone: siRNA-1 alone, siRNA-2 alone, shRNA-1 alone, shRNA-2 alone, miRNA-1 alone and miRNA-2 alone;
2. any 2 of the 6 RNA sequences are combined into an RNA fragment: siRNA-1+ siRNA-2, shRNA-1+ shRNA-2, miRNA-1+ miRNA-2;
3. any 3 of the 6 RNA sequences are combined into an RNA fragment: siRNA-1+ siRNA-2+ shRNA-1, siRNA-1+ siRNA-2+ shRNA-2, siRNA-1+ siRNA-2+ miRNA-1, and siRNA-1+ siRNA-2+ miRNA-2.
The RNA sequences are shown in Table 1 below.
Optionally, the viral vector comprises a promoter and a targeting tag, the targeting tag being capable of forming a targeting structure of the complex structure in an organ tissue of the host, the targeting structure being located on the surface of the complex structure, the complex structure being capable of seeking and binding to a target tissue via the targeting structure, delivering the RNA fragment into the target tissue.
For the explanation of the above viral vectors, RNA fragments, targeting tags, etc. in this example, reference can be made to example 1, which is not described herein again.
The drug can be delivered to target tissues by the RNA delivery system described in example 1 after entering a human body by oral administration, inhalation, subcutaneous injection, intramuscular injection or intravenous injection, and thus, the drug can exert a therapeutic effect.
The medicament of this embodiment may further comprise a pharmaceutically acceptable carrier including, but not limited to, diluents, buffers, emulsions, encapsulating agents, excipients, fillers, adhesives, sprays, transdermal absorbents, humectants, disintegrants, absorption enhancers, surfactants, colorants, flavors, adjuvants, desiccants, adsorbent carriers, and the like.
The dosage form of the drug provided in this embodiment may be tablets, capsules, powders, granules, pills, suppositories, ointments, solutions, suspensions, lotions, gels, pastes, and the like.
The drug can also be used in combination with other drugs for treating pulmonary fibrosis to improve the treatment effect, such as: glucocorticoids, immunosuppressive agents, anticoagulants, and the like.
The drug provided by the embodiment takes the virus as a carrier and the virus carrier as a mature injectant, the safety and reliability of the drug are fully verified, and the drug performance is very good. The RNA sequence which finally exerts the effect is wrapped and conveyed by the endogenous exosome, no immune reaction exists, and the safety of the exosome does not need to be verified. The medicine can deliver various small molecular RNAs and has strong universality. Moreover, the preparation of viral vectors is much cheaper than that of exosomes or substances such as proteins and polypeptides, and is economical. The drugs provided by the present application can be self-assembled with AGO in vivo 2 Tightly bound and enrichedIs a composite structure (exosome), not only can prevent the exosome from being degraded prematurely and maintain the stability of the exosome in circulation, but also is beneficial to the absorption of receptor cells, the intracytoplasmic release and the escape of lysosomes, and the required dosage is low.
Example 3
On the basis of example 1 or 2, the present example provides the use of an RNA delivery system for the treatment of pulmonary fibrosis in a medicament for the treatment of pulmonary fibrosis. This example specifically illustrates the use of the RNA delivery system in the treatment of pulmonary fibrosis in conjunction with the following assay.
In the test, AAV-type 5 adeno-associated virus with high liver affinity is used to wrap anti-miR-21 (miR-21 antisense strand)/TGF-beta 1 siRNA/anti-miR-21 + TGF-beta 1siRNA system to respectively obtain AAV-anti-miR 21/AAV-TGF-beta 1siRNA/AAV-MIX, 100 mu L of titer is 10 mu L by tail vein injection 12 AAV solution at v.g/ml into mice. The in vivo expression of the AAV system was monitored by a small animal living body, and after 3 weeks, stable expression of the AAV system in vivo, particularly in the liver, was observed.
Then selecting a mouse for modeling, and respectively injecting PBS buffer solution/AAV-scrR/AAV-anti-miR 21/AAV-TGF-beta 1siRNA/AAV-MIX (10 mg/kg) into the mouse after the modeling is successful to form a PBS group/AAV-scrR group/AAV-anti-miR 21 group/AAV-TGF-beta 1siRNA group/AAV-MIX group.
The relative TGF-beta 1mRN A levels of normal mice, PBS mice, AAV-scrR mice and AAV-TGF-beta 1siRNA mice are respectively detected, and the results are shown in figure 1B, and it can be seen that the relative TGF-beta 1mRNA levels of the AAV-TGF-beta 1siRNA mice are relatively low.
The relative miR21 mRNA levels of a normal mouse, a PBS group mouse, an AAV-scrR group mouse and an AAV-anti-miR21 group mouse are respectively detected, and the results are shown in figure 1C, and it can be seen that the relative miR21 mRNA levels of the AAV-anti-miR21 group mouse are relatively low.
Hydroxyproline is the major component of collagen, and its content reflects the degree of pulmonary fibrosis. The hydroxyproline content of each group of mice is respectively detected, the result is shown in figure 1A, the hydroxyproline content in the mice of the PBS group and the AAV-scrR group is the highest, the hydroxyproline content in the mice of the AAV-anti-miR21 group, the AAV-TGF-beta 1siRNA group and the AAV-MIX group is lower, and the pulmonary fibrosis of the mice of the AAV-anti-miR21 group, the AAV-TGF-beta 1siRNA group and the AAV-MIX group is inhibited.
The results of Masson trichrome staining of the lungs of each group of mice are shown in FIG. 2, and it can be seen that alveolar spaces of mice in the PBS group and the AAV-scrR group are seriously damaged to cause interstitial pulmonary collagen, while experimental groups such as the AAV-anti-miR21 group, the AAV-TGF-beta 1siRNA group and the AAV-MIX group remarkably reduce the phenomena.
The above experiments demonstrate that CMV-siR is encapsulated by liver-compatible virus miR-21 、CMV-siR TGF-β1 、CMV-siR miR -21+TGF-β1 The circuit can obviously relieve the degree of pulmonary fibrosis, and has great drug potential and clinical research value.
In this document, "upper", "lower", "front", "rear", "left", "right", and the like are used only to indicate relative positional relationships between relevant portions, and do not limit absolute positions of the relevant portions.
In this document, "first", "second", and the like are used only for distinguishing one from another, and do not indicate the degree and order of importance, and the premise that each other exists, and the like.
In this context, "equal", "same", etc. are not strictly mathematical and/or geometric limitations, but also include tolerances as would be understood by a person skilled in the art and allowed for manufacturing or use, etc.
Unless otherwise indicated, numerical ranges herein include not only the entire range within its two endpoints, but also several sub-ranges subsumed therein.
The preferred embodiments and examples of the present application have been described in detail with reference to the accompanying drawings, but the present application is not limited to the embodiments and examples described above, and various changes can be made within the knowledge of those skilled in the art without departing from the concept of the present application.
Claims (19)
1. An RNA delivery system for the treatment of pulmonary fibrosis, comprising a viral vector carrying RNA fragments capable of treating pulmonary fibrosis, said viral vector being capable of enriching in a host's organ tissue and spontaneously forming endogenously in said host's organ tissue a complex structure comprising said RNA fragments capable of treating pulmonary fibrosis, said complex structure being capable of delivering said RNA fragments into the lungs for the treatment of pulmonary fibrosis.
2. The RNA delivery system of claim 1, wherein the viral vector is an adeno-associated virus.
3. The RNA delivery system for treating pulmonary fibrosis of claim 2, wherein the adeno-associated virus is adeno-associated virus type 5, adeno-associated virus type 8, or adeno-associated virus type 9.
4. The RNA delivery system for treating pulmonary fibrosis of claim 1, wherein the RNA segment comprises 1, two or more specific RNA sequences of medical significance which are siRNA, shRNA or miRNA of medical significance.
5. The RNA delivery system of claim 1, wherein the viral vector comprises a promoter and a targeting tag, wherein the targeting tag is capable of forming a targeting moiety of the complex structure in an organ tissue of the host, wherein the targeting moiety is located on a surface of the complex structure, and wherein the complex structure is capable of targeting and binding a target tissue via the targeting moiety to deliver the RNA fragment into the target tissue.
6. The RNA delivery system for the treatment of pulmonary fibrosis of claim 5, wherein the viral vector comprises any one or a combination of the following: promoter-RNA fragment, promoter-targeting tag, promoter-RNA fragment-targeting tag; each viral vector comprises at least one RNA segment and one targeting label, wherein the RNA segment and the targeting label are positioned in the same line or different lines.
7. The RNA delivery system for the treatment of pulmonary fibrosis of claim 6, wherein the viral vector further comprises flanking sequences, compensation sequences and loop sequences that enable the lines to fold into the correct structure and to be expressed, the flanking sequences comprising a 5 'flanking sequence and a 3' flanking sequence;
the virus vector comprises any one line or combination of several lines: 5 '-promoter-5' flanking sequence-RNA fragment-loop sequence-compensating sequence-3 'flanking sequence, 5' -promoter-targeting label-5 'flanking sequence-RNA fragment-loop sequence-compensating sequence-3' flanking sequence.
8. The RNA delivery system for treating pulmonary fibrosis of claim 7, wherein the 5' flanking sequence is ggatcctggaggcttgctgaaggtgctgtatgctgaattc or a sequence having greater than 80% homology thereto;
the loop sequence is gtttggccactgactgac or a sequence with homology more than 80 percent;
<xnotran> 3' accggtcaggacacaaggcctgttactagcactcacatggaacaaatggcccagatctggccgcactcgag 80% ; </xnotran>
The compensation sequence is a reverse complementary sequence of the RNA segment, and any 1-5 bases in the RNA segment are deleted.
9. The RNA delivery system for the treatment of pulmonary fibrosis of claim 6, wherein, in the presence of at least two of the lines in the viral vector, adjacent lines are connected by a sequence consisting of sequences 1-3;
wherein, the sequence 1 is CAGATC, the sequence 2 is a sequence consisting of 5-80 bases, and the sequence 3 is TGGATC.
10. The RNA delivery system for the treatment of pulmonary fibrosis of claim 9, wherein in the presence of at least two of the lines in the viral vector, adjacent lines are connected by sequence 4 or a sequence having greater than 80% homology to sequence 4;
wherein the sequence 4 is CAGATCTGGCCGCACTCGAGGTAGTGAGTCGACGACCAGTGGAC.
11. The RNA delivery system for treating pulmonary fibrosis of claim 1, wherein the organ tissue is the liver and the complex structure is an exosome.
12. The RNA delivery system for the treatment of pulmonary fibrosis of claim 5, wherein the targeting tag is selected from a targeting peptide or a targeting protein with targeting function.
13. The RNA delivery system for treating pulmonary fibrosis of claim 12, wherein the targeting peptide comprises RVG targeting peptide, GE11 targeting peptide, PTP targeting peptide, TCP-1 targeting peptide, MSP targeting peptide;
the target protein comprises RVG-LAMP2B fusion protein, GE11-LAMP2B fusion protein, PTP-LAMP2B fusion protein, TCP-1-LAMP2B fusion protein and MSP-LAMP2B fusion protein.
14. A viral vector-based RNA delivery system according to claim 4, wherein the RNA sequence is 15-25 nucleotides in length.
15. The RNA delivery system for the treatment of pulmonary fibrosis of claim 14, wherein the RNA capable of treating pulmonary fibrosis is selected from any one or several of the following RNAs: an antisense strand of miRNA-21, an siRNA of TGF-beta 1 gene, or an RNA sequence having a homology of greater than 80% with the above sequence, or a nucleic acid molecule encoding the above RNA.
16. The RNA delivery system of claim 15, wherein the siRNA of TGF- β 1 gene comprises acggaaauaacccuagugggc, ugaaccuuguaagauuucgu, uugaagaacauauauauaugcug, ucuaacagugguguccc, ucucagguccucag, other sequences that inhibit expression of TGF- β 1 gene, and sequences that have greater than 80% homology to the above sequences.
17. The viral vector-based RNA delivery system of claim 1, wherein the delivery system is a delivery system for use in a mammal, including a human.
18. Use of an RNA delivery system according to any of claims 1 to 17 for the treatment of pulmonary fibrosis in medicine.
19. The use of claim 18, wherein the medicament is for the treatment of pulmonary fibrosis and related conditions, and the administration of the medicament comprises oral administration, inhalation, subcutaneous injection, intramuscular injection, and intravenous injection.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110340997 | 2021-03-30 | ||
| CN2021103409975 | 2021-03-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115137737A true CN115137737A (en) | 2022-10-04 |
Family
ID=83407104
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210325708.9A Pending CN115137737A (en) | 2021-03-30 | 2022-03-29 | RNA delivery system for treating pulmonary fibrosis |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN115137737A (en) |
| WO (1) | WO2022206784A1 (en) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015002956A1 (en) * | 2013-07-01 | 2015-01-08 | Ohio State Innovation Foundation | Exosome delivery system |
| CN111225682A (en) * | 2017-10-20 | 2020-06-02 | 吉尼松公司 | Use of syncytin for targeted delivery of drugs and genes to lung tissue |
| CN110885789A (en) * | 2018-09-05 | 2020-03-17 | 中国科学院生物物理研究所 | Preparation of engineered exosome of efficient controllable packaging endogenous nucleic acid and application thereof |
| EP4022074A4 (en) * | 2019-08-27 | 2023-11-15 | The Trustees of Columbia University in the City of New York | Engineered exosomes for targeted delivery |
-
2022
- 2022-03-29 WO PCT/CN2022/083823 patent/WO2022206784A1/en active Application Filing
- 2022-03-29 CN CN202210325708.9A patent/CN115137737A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022206784A1 (en) | 2022-10-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107075515B (en) | C/EBP alpha compositions and methods of use | |
| JP2010532163A5 (en) | ||
| CN108220293A (en) | A kind of small RNA and medical composition and its use | |
| US20240141380A1 (en) | Viral vector-based rna delivery system and use thereof | |
| CN115137742A (en) | RNA delivery system for treating obesity | |
| WO2023051822A1 (en) | Targeting oligonucleotide for treating diseases associated with pcsk9 | |
| CN115137737A (en) | RNA delivery system for treating pulmonary fibrosis | |
| Yao et al. | Nucleic acid nanomaterials-based therapy for osteoarthritis: Progress and prospects | |
| CN114958850A (en) | Gene assembly, delivery system containing same and application thereof | |
| EP4317434A1 (en) | Rna delivery system for treatment of huntington's disease | |
| CN102188719B (en) | Application of EB virus miR-BART3 antisense oligonucleotides in preparing medicament for treating nasopharyngeal darcinoma | |
| WO2022206781A1 (en) | Rna delivery system for treating colitis | |
| CN115137739A (en) | RNA delivery system for treating lung cancer | |
| WO2022206814A1 (en) | Rna delivery system for treating glioblastoma | |
| WO2022206821A1 (en) | Rna delivery system for treating parkinson's disease | |
| CN115137743A (en) | RNA plasmid delivery system for treating pulmonary fibrosis | |
| CN115385988B (en) | MMP enzyme response type tumor targeting polypeptide carrier and application thereof | |
| WO2022206812A1 (en) | Rna delivery system for treating cancer | |
| CN104087574B (en) | A method of being used to prepare liver cell targeting transmission siRNA | |
| WO2022206816A1 (en) | Rna plasmid delivery system for treating parkinson's disease | |
| WO2022206802A1 (en) | Rna plasmid delivery system for treating glioblastoma | |
| CN115141845A (en) | RNA plasmid delivery system for treating lung cancer | |
| CN116004623B (en) | shRNA sequence for targeted silencing of LRP1 gene expression, preparation method and application thereof | |
| WO2022153846A1 (en) | Composition for treating cancer and composition for suppressing angiogenesis | |
| CN102218148A (en) | Use of epstein-barr virus miR-BART1-5p antisense oligonucleotide in preparing drugs for treating nasopharyngeal carcinoma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |